Valuation : Zeo ScientifiX, Inc.

Market Cap 9.4M 8.09M 7.59M 6.95M 12.97M 889M 13.07M 89.83M 34.98M 454M 35.32M 34.55M 1.46B P/E 2024
-2.29x
P/E 2025 -2.17x
Enterprise Value 9.54M 8.21M 7.7M 7.05M 13.15M 902M 13.25M 91.09M 35.47M 461M 35.81M 35.03M 1.48B EV / Sales 2024
2.43x
EV / Sales 2025 2.45x
Free-Float
50.57%
Yield 2024 *
-
Yield 2025 -
06-15 Zeo ScientifiX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 CI
06-09 Zeo Scientifix, Inc. Announces Management Changes CI
04-09 Zeo Scientifix Inc - enters MoU with Regen Therapy for exclusive scientific and biologics collaboration - SEC filing RE
04-09 Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics-Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO Scientifix CI
03-27 Zeo Scientifix, Inc. Announces Termination of Dr. John D. Kisiday as Chief Science Officer Effective March 23, 2026 CI
03-17 Zeo ScientifiX, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026 CI
01-29 Zeo ScientifiX, Inc. Reports Earnings Results for the Full Year Ended October 31, 2025 CI
01-28 Zeo ScientifiX, Inc. Auditor Raises 'Going Concern' Doubt CI
01-28 Zeo Scientifix, Inc. Appoints John D. Kisiday as Chief Science Officer, Effective January 23, 2026 CI
01-07 Cytora Therapeutics, Made Scientific, and Zeo Scientifix Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States CI
01-07 Cytora Therapeutics partners with Made Scientific, and Zeo Scientifix to manufacture allogeneic stem cell therapy RE
01-05 Zeo ScientifiX, Inc. Appoints Ian T. Bothwell as Full-Time Chief Executive Officer, Effective December 24, 2025 CI
12-03 Zeo Scientifix, Inc. Terminates Ron Borsheim as Chief Sales Officer Aesthetics, Effective November 30, 2025 CI
1 week-4.00%
Current month-9.09%
1 month-10.45%
3 months-36.51%
6 months-45.95%
Current year-55.72%
1 week 1.2
Extreme 1.2
1.32
1 month 1.17
Extreme 1.17
1.62
Current year 0.97
Extreme 0.97
2.98
1 year 0.97
Extreme 0.97
2.99
3 years 0.8
Extreme 0.8
4.73
5 years 0.8
Extreme 0.8
22
10 years 0.7
Extreme 0.7
125.98
Manager TitleAgeSince
Chief Executive Officer 65 2024-05-31
Chief Tech/Sci/R&D Officer - 2019-12-31
Compliance Officer - 2025-03-31
Director TitleAgeSince
Director/Board Member 65 2019-09-10
Director/Board Member 78 2022-09-22
Director/Board Member 64 2022-08-18
Date Insider Type Main position Quantity % Market Cap. Importance
6/10/26 Free

Chief Executive Officer

1,250,000 16.0721%
1/23/26 Other

Chief Technology Officer

50,000 0.7632%
1/14/26
Greyt Ventures LLC
FreeCompany 175,000 2.6713%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.00%-20.53%-67.57% 9.4M
-0.37%+3.47%+33.37%+123.45% 108B
+1.27%+5.73%+65.12%+183.87% 57.1B
+0.74%+1.12%-10.56%+243.04% 22.36B
+0.55%+1.04%-11.04%-7.85% 8.12B
+1.22%-0.79%-39.05%-28.02% 7.08B
+0.36%+6.02%+10.67%+26.08% 6.78B
+1.10%-2.01%-15.21%-32.13% 6.1B
-0.42%-0.95%-4.59%+19.57% 5.12B
+1.23%+8.02%+310.32%+478.99% 4.45B
Average +0.56%+1.46%+31.85%+93.94% 22.49B
Weighted average by Cap. +0.33%+2.16%+35.79%+138.66%

Financials

2024 2025
Net sales 4.62M 3.98M 3.73M 3.41M 6.37M 437M 6.42M 44.13M 17.19M 223M 17.35M 16.97M 719M 5.2M 4.47M 4.2M 3.84M 7.17M 491M 7.23M 49.66M 19.34M 251M 19.52M 19.1M 809M
Net income -4.7M -4.05M -3.8M -3.48M -6.49M -445M -6.54M -44.94M -17.5M -227M -17.67M -17.28M -732M -5.52M -4.75M -4.46M -4.08M -7.61M -522M -7.67M -52.73M -20.54M -267M -20.73M -20.28M -859M
Net Debt 36K 30.97K 29.07K 26.59K 49.64K 3.4M 50.03K 344K 134K 1.74M 135K 132K 5.6M 132K 114K 107K 97.51K 182K 12.48M 183K 1.26M 491K 6.38M 496K 485K 20.54M
Logo Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. The Company is primarily focused on developing innovative biological therapeutics for regenerative medicine and the treatment of degenerative diseases. Its proprietary products, including Zofin, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles, and Patient Pure X (PPX), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry administered through doctors and clinics. It has developed and begun to distribute additional products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications and is actively exploring further development of additional products to be used in other topical aesthetic applications.
Employees
20
Date Price Change Volume
26-09-03 US$1.200 0.00% 1,181
26-09-01 US$1.200 -9.09% 4,322
26-08-31 US$1.320 +4.76% 2,850
26-08-28 US$1.260 +0.80% 603
26-08-27 US$1.250 +6.84% 1,458
  1. Stock Market
  2. Stocks
  3. ZEOX Stock